Skip to main content
Premium Trial:

Request an Annual Quote

Consultancy Buys Majority Stake in Proteomics Shop BioMachines

This article has been updated to correct the spelling of Larrichio's former company.


NEW YORK, Feb. 1 (GenomeWeb News) - Clearview Limited, a Raleigh, NC-based consulting and advisory firm, has purchased a majority stake in BioMachines, a sample prep proteomics company located in Research Triangle Park, NC, the companies said today.


Clearview's stake gives the company "full transactional authority. It is less than 75 percent and greater than 60" said Biomachines' new chairman, Sam Tetlow.


Tetlow added that the acquisition "delivers a new commercial focus to the company," which has been developing products for five years.


The acquisition took place on Dec. 29, 2005, but was disclosed today to coincide with the release of BioMachine's new TMiD MALDI, Tetlow told GenomeWeb News.


Tetlow is the founding partner of Clearview and a principal with Research Triangle Ventures.


Tom Larrichio, a former vice president at TriVirix International, has been named CEO.


Additional details were not provided.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.